aprepitanthttp://www.unboundmedicine.com/medline/ebm/research/aprepitantUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.A theoretical-empirical analysis on the initial dissolution rate of drugs from polydispersed particles.http://www.unboundmedicine.com/medline/ebm/record/19881303/full_citation/A_theoretical_empirical_analysis_on_the_initial_dissolution_rate_of_drugs_from_polydispersed_particles_Takano R, Takata N, Shiraki K, et al. 
A theoretical-empirical analysis on the initial dissolution rate of drugs from polydispersed particles. [Journal Article]
Biol Pharm Bull 2009 Nov; 32(11):1885-91.
Abstract | Full CitationAprepitant as an antipruritic agent?http://www.unboundmedicine.com/medline/ebm/record/19797294/full_citation/Aprepitant_as_an_antipruritic_agentDuval A, Dubertret L 
Aprepitant as an antipruritic agent? [Case Reports, Letter]
N Engl J Med 2009 Oct 1; 361(14):1415-6.
Full Citation | Find Related Articles Aprepitant-associated ifosfamide neurotoxicity.http://www.unboundmedicine.com/medline/ebm/record/19759053/full_citation/Aprepitant_associated_ifosfamide_neurotoxicity_Ho H, Yuen C 
Aprepitant-associated ifosfamide neurotoxicity. [JOURNAL ARTICLE]
J Oncol Pharm Pract 2009 Sep 16.
Full Citation | Publisher Full Text | Find Related Articles Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.http://www.unboundmedicine.com/medline/ebm/record/19756774/full_citation/Evaluation_of_risk_factors_predictive_of_nausea_and_vomiting_with_current_standard_of_care_antiemetic_treatment:_analysis_of_two_phase_III_trials_of_aprepitant_in_patients_receiving_cisplatin_based_chemotherapy_Hesketh PJ, Aapro M, Street JC, et al. 
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. [JOURNAL ARTICLE]
Support Care Cancer 2009 Sep 12.
Abstract | Full CitationAprepitant: a review of its use in the prevention of nausea and vomiting.http://www.unboundmedicine.com/medline/ebm/record/19719336/full_citation/Aprepitant:_a_review_of_its_use_in_the_prevention_of_nausea_and_vomiting_Curran MP, Robinson DM 
Aprepitant: a review of its use in the prevention of nausea and vomiting. [Journal Article]
Drugs 2009; 69(13):1853-78.
Abstract | Full CitationLack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.http://www.unboundmedicine.com/medline/ebm/record/19608812/full_citation/Lack_of_effect_of_aprepitant_or_its_prodrug_fosaprepitant_on_QTc_intervals_in_healthy_subjects_Marbury TC, Jin B, Panebianco D, et al. 
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. [Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Anesth Analg 2009 Aug; 109(2):418-25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.http://www.unboundmedicine.com/medline/ebm/record/19574198/full_citation/Why_cerebellar_glioblastoma_is_rare_and_how_that_indicates_adjunctive_use_of_the_FDA_approved_anti_emetic_aprepitant_might_retard_cerebral_glioblastoma_growth:_a_new_hypothesis_to_an_old_question_Kast RE 
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. [JOURNAL ARTICLE]
Clin Transl Oncol 2009 Jul; 11(7):408-410.
Full CitationAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.http://www.unboundmedicine.com/medline/ebm/record/19568773/full_citation/Aprepitant_for_the_prevention_of_chemotherapy_induced_nausea_and_vomiting_associated_with_a_broad_range_of_moderately_emetogenic_chemotherapies_and_tumor_types:_a_randomized_double_blind_study_Rapoport BL, Jordan K, Boice JA, et al. 
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. [JOURNAL ARTICLE]
Support Care Cancer 2009 Jul 1.
Abstract | Full Citation | Find Related Articles NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers.http://www.unboundmedicine.com/medline/ebm/record/19545476/full_citation/NK1_receptor_antagonism_and_the_neural_processing_of_emotional_information_in_healthy_volunteers_McCabe C, Cowen PJ, Harmer CJ 
NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. [JOURNAL ARTICLE]
Int J Neuropsychopharmacol 2009 Jun 23.:1-14.
Abstract | Full Citation | Find Related Articles Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.http://www.unboundmedicine.com/medline/ebm/record/19541792/full_citation/Randomized_double_blind_dose_ranging_trial_of_the_oral_neurokinin_1_receptor_antagonist_casopitant_mesylate_for_the_prevention_of_cisplatin_induced_nausea_and_vomiting_Roila F, Rolski J, Ramlau R, et al. 
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. [JOURNAL ARTICLE]
Ann Oncol 2009 Jun 18.
Abstract | Full Citation | Find Related Articles